These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 18243516)

  • 21. Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction.
    Akbar M; Abel R; Seyler TM; Bedke J; Haferkamp A; Gerner HJ; Möhring K
    BJU Int; 2007 Sep; 100(3):639-45. PubMed ID: 17532858
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study.
    Athanasopoulos A; Gyftopoulos K; Giannitsas K; Fisfis J; Perimenis P; Barbalias G
    J Urol; 2003 Jun; 169(6):2253-6. PubMed ID: 12771763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections.
    Gamé X; Castel-Lacanal E; Bentaleb Y; Thiry-Escudié I; De Boissezon X; Malavaud B; Marque P; Rischmann P
    Eur Urol; 2008 Mar; 53(3):613-8. PubMed ID: 17804150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in urodynamic parameters after tolterodine treatment for female overactive bladder syndrome with or without voiding dysfunction.
    Wu WY; Hsiao SM; Chang TC; Lin HH
    J Obstet Gynaecol Res; 2011 May; 37(5):436-41. PubMed ID: 21272154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Botulinum toxin type A injections for treating neurogenic detrusor overactivity combined with low-compliance bladder in patients with spinal cord lesions.
    Klaphajone J; Kitisomprayoonkul W; Sriplakit S
    Arch Phys Med Rehabil; 2005 Nov; 86(11):2114-8. PubMed ID: 16271557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urodynamic effects of propiverine in children and adolescents with neurogenic bladder: results of a prospective long-term study.
    Schulte-Baukloh H; Mürtz G; Heine G; Austin P; Miller K; Michael T; Strugala G; Knispel HH
    J Pediatr Urol; 2012 Aug; 8(4):386-92. PubMed ID: 21907623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial.
    Fader M; Glickman S; Haggar V; Barton R; Brooks R; Malone-Lee J
    J Urol; 2007 Jan; 177(1):208-13; discussion 213. PubMed ID: 17162046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Supratrigonal cystectomy with Hautmann pouch as treatment for neurogenic bladder in spinal cord injury patients: long-term functional results.
    Gobeaux N; Yates DR; Denys P; Even-Schneider A; Richard F; Chartier-Kastler E
    Neurourol Urodyn; 2012 Jun; 31(5):672-6. PubMed ID: 22532256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Postpubertal urodynamic and upper urinary tract changes in children with conservatively treated myelomeningocele.
    Almodhen F; Capolicchio JP; Jednak R; El Sherbiny M
    J Urol; 2007 Oct; 178(4 Pt 1):1479-82. PubMed ID: 17706702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of tolterodine in children with neurogenic detrusor overactivity: relationship between dose and urodynamic response.
    Ellsworth PI; Borgstein NG; Nijman RJ; Reddy PP
    J Urol; 2005 Oct; 174(4 Pt 2):1647-51; discussion 1651. PubMed ID: 16148673
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy.
    Serati M; Salvatore S; Uccella S; Cromi A; Khullar V; Cardozo L; Bolis P
    Eur Urol; 2008 Oct; 54(4):911-5. PubMed ID: 18036728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury.
    O'Leary M; Erickson JR; Smith CP; McDermott C; Horton J; Chancellor MB
    J Spinal Cord Med; 2003; 26(2):159-62. PubMed ID: 12828295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients.
    Haferkamp A; Staehler G; Gerner HJ; Dörsam J
    Spinal Cord; 2000 Apr; 38(4):250-4. PubMed ID: 10822396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical and urodynamic effects of oral propiverine therapy in neurogenic urinary incontinence. A multicenter study for optimizing dosage].
    Mazur D; Göcking K; Wehnert J; Schubert G; Herfurth G; Alken RG
    Urologe A; 1994 Sep; 33(5):447-52. PubMed ID: 7974935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
    Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
    Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination drug therapy improves compliance of the neurogenic bladder.
    Cameron AP; Clemens JQ; Latini JM; McGuire EJ
    J Urol; 2009 Sep; 182(3):1062-7. PubMed ID: 19616807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study.
    Gacci M; Del Popolo G; Macchiarella A; Celso M; Vittori G; Lapini A; Serni S; Sandner P; Maggi M; Carini M
    J Urol; 2007 Nov; 178(5):2040-3; discussion 2044. PubMed ID: 17869296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study.
    Ehren I; Volz D; Farrelly E; Berglund L; Brundin L; Hultling C; Lafolie P
    Scand J Urol Nephrol; 2007; 41(4):335-40. PubMed ID: 17763227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term intravesical oxybutynin chloride therapy in children with myelodysplasia.
    Painter KA; Vates TS; Bukowski TP; Fleming P; Freedman AL; Smith CA; Gonzalez R; Perlmutter AD
    J Urol; 1996 Oct; 156(4):1459-62. PubMed ID: 8808907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effects of long-term administration of oxybutynin hydrochloride (KL007) for the treatment of neurogenic bladder and unstable bladder].
    Sonoda T; Sakurai T; Yamada K; Mizutani S; Tsujimoto Y; Ogawa T
    Hinyokika Kiyo; 1989 Jan; 35(1):167-78. PubMed ID: 2658513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.